Vanta Bioscience Ltd is in the business of Preclinical Activities.Business Overview: The company is a preclinical contract research organization, offering preclinical safety assessment services for clientele from the Pharmaceutical, Medical Devices, Nutraceuticals, Feed additives, Biotech, Agrochemicals, Cosmetics, and Chemical industries. In addition, the company also provides risk assessment services for...
Outcome of Board Meeting held on 05.09.2026 - 10th AGM to be held on 30.09.2026
Audited standalone and consolidated Financial Results for the half year and financial year ended March 31, 2026
Vanta Bioscience board cleared FY26 & H2 financial results. MD Dopesh Raja Mulakala re-appointed for 3 years (shareholder approval pending). Auditors gave a clean report. Subsidiary assets stood at ₹3.94 Cr, with H2 & FY26 net losses of ₹0.01 Cr each.
VANTABIO has announced a board meeting on May 30, 2026, to approve financial results for the half-year and full financial year ended March 31, 2026. Trading window for designated persons remains closed until June 1, 2026.
Vanta Bioscience Limited has confirmed its compliance regarding shareholder share transfer activities by submitting a certificate from its Registrar and Share Transfer Agent. This document assures investors that requests for dematerialization and rematerialization of shares were processed efficiently and properly for the recent quarter. This update highlights the company's commitment...
